Tasos Konidaris - Mar 5, 2025 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role: Executive Vice President & CFO
Signature: /s/ Denis Butkovic, Attorney-in-Fact
Stock symbol: AMRX
Transactions as of: Mar 5, 2025
Transactions value $: -$891,000
Form type: 4
Date filed: 3/7/2025, 04:17 PM
Previous filing: Mar 5, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMRX	Class A Common Stock	Sale	-$891K	-100K	-13.85%	$8.91	622K	Mar 5, 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.84 to $8.98 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

Content

The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.84 to $8.98 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.